You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Asia Pacific Lancet and Pen Needles Market size at USD 1,416.30 million in 2023. During the ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk A/S has moved -53.6% over the last year, and the S&P 500 logged a change of 5.4% NVO has an average analyst rating of buy and is -43.38% away from its mean target price of $102.64 per ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. Despite ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight ... a pill is easier to take on the go and doesn't require a needle stick. That could spur demand for this sort of product.

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.